Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
November 30, 2021 07:30 ET
|
Bright Minds Biosciences
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia,...
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
November 03, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
October 06, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences Provides Scientific Update
September 22, 2021 07:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance
September 08, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
August 18, 2021 07:00 ET
|
Bright Minds Biosciences
-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was...
Bright Minds Biosciences Announces Application to List on Nasdaq
June 16, 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team
June 14, 2021 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on...
Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond
June 11, 2021 08:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on...
Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI
June 09, 2021 16:30 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on...